



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 1, 2005

Signature: 
(Sharon M. Siplich)

Docket No.: 28335/39196A
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Info Patent Application of:
Lauren O. Bakaletz et al.

Application No.: 10/807,746

Confirmation No.: 6532

Filed: March 24, 2004

Art Unit: 1645

For: Nontypeable Haemophilus Influenzae
Virulence Factors

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. A copy of document C29 listed on the Form PTO-1449 is submitted herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


This Information Disclosure Statement is being submitted before receipt of the first official action on the merits in the above-identified patent application. Accordingly, it is believed no fee is due in this matter pursuant to 37 C.F.R. § 1.97(b). The Commissioner is authorized to charge any fee due related to this statement to Deposit Account No. 13-2855.

Dated: November 1, 2005

Respectfully submitted,

By 
Sharon M. Sintich
Registration No.: 48,484
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.
28335/39196ASerial No.
10/807,746Applicant(s)
Bakaletz et al.Filing Date
March 24, 2004Art Unit
1645**INFORMATION DISCLOSURE STATEMENT****U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No

OTHER DOCUMENTS

C29	Genbank Accession No. P45285 Fleischmann, <i>et al.</i> , "Peptide Transport Periplasmic Protein sapA Precursor" (September 13, 2005).
-----	--

EXAMINER:

DATE CONSIDERED: